The Global Molecular Diagnostics Partnering 2014-2019 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.
The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 600 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.
Key benefits
Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of Molecular Diagnostics deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
- Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
- Identify most active Molecular Diagnostics dealmakers since 2014
- Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Molecular Diagnostics trends and structure of deals entered into by leading companies worldwide.
Molecular Diagnostics Partnering Terms and Agreements includes:
- Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2014
- Analysis of Molecular Diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Molecular Diagnostics deals
- Access to Molecular Diagnostics contract documents
- Leading Molecular Diagnostics deals by value since 2014
- Most active Molecular Diagnostics dealmakers since 2014
In Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 600 Molecular Diagnostics deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Molecular Diagnostics Partnering 2014-2019 report provides the reader with the following key benefits:
- In-depth understanding of Molecular Diagnostics deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
- Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
- Identify most active Molecular Diagnostics dealmakers since 2014
- Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Molecular Diagnostics dealmaking
2.1. Introduction
2.2. Molecular Diagnostics partnering over the years
2.3. Most active Molecular Diagnostics dealmakers
2.4. Molecular Diagnostics partnering by deal type
2.5. Molecular Diagnostics partnering by therapy area
2.6. Deal terms for Molecular Diagnostics partnering
2.6.1 Molecular Diagnostics partnering headline values
2.6.2 Molecular Diagnostics deal upfront payments
2.6.3 Molecular Diagnostics deal milestone payments
2.6.4 Molecular Diagnostics royalty rates
Chapter 3 – Leading Molecular Diagnostics deals
3.1. Introduction
3.2. Top Molecular Diagnostics deals by value
Chapter 4 – Most active Molecular Diagnostics dealmakers
4.1. Introduction
4.2. Most active Molecular Diagnostics dealmakers
4.3. Most active Molecular Diagnostics partnering company profiles
Chapter 5 – Molecular Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular Diagnostics contracts dealmaking directory
Chapter 6 – Molecular Diagnostics dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Molecular Diagnostics deals by company A-Z
Appendix 2 – Molecular Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 – Molecular Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 – Molecular Diagnostics deals by therapy area
Appendix 5 –Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Molecular Diagnostics partnering since 2014
Figure 2: Active Molecular Diagnostics dealmaking activity– 2014 to 2019
Figure 3: Molecular Diagnostics partnering by deal type since 2014
Figure 4: Molecular Diagnostics partnering by disease type since 2014
Figure 5: Molecular Diagnostics deals with a headline value
Figure 6: Molecular Diagnostics deals with an upfront value
Figure 7: Molecular Diagnostics deals with a milestone value
Figure 8: Molecular Diagnostics deals with a royalty rate value
Figure 9: Top Molecular Diagnostics deals by value since 2014
Figure 10: Most active Molecular Diagnostics dealmakers 2014 to 2019
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Pricing options
- $2,995: single-user
- $4,495: multi-user
- $8,995: single site license
- $14,995: global site license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by SagePay.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
